Increasing the actions of the calcium pump SERCA1 may prove helpful in muscular dystrophies no matter which genetic mutation is causing the dystrophy, a study published in the Feb. 1, 2011, issue of the Journal of Clinical Investigation showed. Read More
Privately held Scil Proteins GmbH, of Halle, Germany, has concluded a financing round with BioNet Holding GmbH, worth €24 million ($33.1 million). The funds will be used to move two preclinical products derived from Scil Proteins' Affilin scaffold technology platform into Phase I studies over the next three years. Read More
Metamark Genetics Inc., of Cambridge, Mass., reported that a prostate cancer study published in Nature described the identification of a key tumor suppressor of prostate cancer progression in mice and humans, and revealed four markers that are predictive of biochemical recurrence and lethal metastasis in human prostate cancer. Read More
United Therapeutics Corp., of Silver Spring, Md., said it completed enrollment in its FREEDOM-M registration trial testing a sustained-release, oral formulation of treprostinil diethanolamine in pulmonary arterial hypertension (PAH) patients not receiving any other approved PAH therapy. The study enrolled 349 patients, above the target enrollment of 315. Read More
Stock in Chelsea Therapeutics International Ltd. tumbled 18.5 percent on Wednesday after the company reported that an interim analysis had found their Phase III (306) trial of Northera (droxidopa) for neurogenic orthostatic hypotension (NOH) in Parkinson's patients to be futile. Read More
Seattle Genetics Inc. expects to fund potential regulatory approval and the commercial launch of brentuximab vedotin, its candidate in Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL), with some of the $155 million grossed from an underwritten public offering of 10 million shares of common stock at $15.50 per share, about 4 percent below Tuesday's closing price. Read More
